Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Revenue projections:

Revenue projections for LH
Revenue projections for LH

With LH's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 1.424000
forwardPE 13.609469
debtToEquity 75.561000
earningsGrowth 0.157000
revenueGrowth 0.056000
grossMargins 0.287600
operatingMargins 0.105500
trailingEps 10.470000
forwardEps 19.285470

LH's current ratio of 1.424 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, LH can comfortably cover its liabilities, reflecting a strong financial outlook.
LH's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
LH's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with LH anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for LH
Price projections for LH

Labcorp Holdings Inc.'s price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in Labcorp Holdings Inc.'s ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for LH
Insider Transactions for LH


28 LH sales were executed, with market price at 263.7654021126883.During the period under consideration, no sell transactions took place.The higher number of buys versus sells near Labcorp Holdings Inc.'s current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for LH
Recommendations trend for LH


LH has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see LH as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.